Sometimes called vitamin B8, it helps the body metabolize nutrients and discourages fatty buildup in the heart and liver
This multi-receptor approach distinguishes it from existing licensed medicines such as semaglutide (Ozempic, Wegovy) or tirzepatide licensed in the UK as Mounjaro for type 2 diabetes and as Zepbound for obesity which act on fewer receptor pathways
When you combine Peptide Therapy with B12 injections you get a dual-action approach that accelerates fat metabolism, improves recovery, and sustains energy for workouts and daily life
Preclinical studies demonstrate elevated intracellular NAD+ levels following NNMT inhibition, suggesting a role in metabolic energy regulation
Both semaglutide and liraglutide are MHRA-approved and are supported by NICE technology appraisals TA875 for semaglutide and TA664 for liraglutide which set out specific eligibility criteria
Follow UK Chems handling and storage recommendations for best results